Novartis has secured regulatory approval in Switzerland for Coartem Baby, the first malaria treatment designed for newborns and young infants, addressing a major treatment gap. The company plans to distribute the drug largely on a not-for-profit basis in select regions, aiming to enhance care for vulnerable infant populations in malaria-endemic areas. This approval followed earlier regulatory focus and represents a milestone in pediatric malaria therapeutics.